PDCD1 and classic Hodgkin lymphoma: These findings provided the rationale for targeting the PD-1/PD-L1 pathway in relapsed/refractory cHL, leading to the accelerated FDA approval of the PD-1 inhibitors nivolumab [8] and pembrolizumab [113] in 2016 and 2017, respectively.